Pediatrics open science
Estimated SARS-CoV-2 Seroprevalence Among Children: United States, September 2021 to December 2022
By Bratcher A, Deng Y, Deng X and 10 others.
Abstract
Background
Studying seroprevalence, the prevalence of SARS-CoV-2 antibodies in blood, produces more reliable estimates of infection burden compared with diagnosed cases. In this analysis, United States Nationwide Commercial Laboratory Seroprevalence Study data are used to calculate pediatric seroprevalence trends and their correlation with state-level vaccination.
Methods
We tested SARS-CoV-2 antibodies residual serum specimens from pediatric patients during September 2021 to December 2022 for (1) presence of antinucleocapsid (anti-N; infection-induced) antibodies and (2) semiquantitative anti-spike protein (anti-S; vaccination- and infection-induced) immunoglobulin G antibody concentrations. Seroprevalence trends and antibody concentrations by age group over time were evaluated. State-level correlations were calculated between geometric mean concentrations and vaccination data.